Crohn Disease Clinical Trials

37 studies are recruiting for crohn disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

   This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California Davis Comprehensive Cancer Center, Sacramento, California

   Locations

   52 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03816345 on ClinicalTrials.gov

2. Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

   Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). An extension study is a type of study where people who received tulisokibart in …

   Stage

   Phase 3

   Ages

   Any age

   Site

   Connecticut Clinical Research Institute ( Site 0297), Bristol, Connecticut

   Locations

   37 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06651281 on ClinicalTrials.gov

3. Standardized Microbiota Transplant Therapy in Crohn's Disease

   Crohn's disease (CD) develops because of a disruption of homeostasis between the gut microbiota and the host immune system resulting in excessive inflammation in the intestinal tract. Current drug therapies for CD are directed at the immune system. The emergence of fecal microbiota transplantation …

   Stage

   Phase 2

   Ages

   18 to 89

   Site

   University of Minnesota, Minneapolis, Minnesota

   Locations

   3 in total

   Run by

   University of Minnesota

   See if you can join NCT06631586 on ClinicalTrials.gov

4. A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

   Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adu…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Biopharma Informatic, LLC, Los Angeles, California

   Locations

   70 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07483073 on ClinicalTrials.gov

5. A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

   The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protoc…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Om Research LLC, Oxnard, California

   Locations

   70 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07483099 on ClinicalTrials.gov

6. A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

   The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).

   Stage

   Not phased

   Ages

   18 and older

   Site

   BAMC, Houston, Texas

   Run by

   Janssen Scientific Affairs, LLC

   See if you can join NCT04372108 on ClinicalTrials.gov

7. A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

   The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   AZ Gastro Care, Chandler, Arizona

   Locations

   370 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07196722 on ClinicalTrials.gov

8. A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

   The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Digestive Health Specialists of the Southeast, Dothan, Alabama

   Locations

   160 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07499232 on ClinicalTrials.gov

9. A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

   The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive [worsens with time] and life-threatening disease of the intesti…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinnova Research, Anaheim, California

   Locations

   142 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07577843 on ClinicalTrials.gov

10. A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

    The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications.

    Stage

    Phase 4

    Ages

    18 and older

    Site

    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT07654751 on ClinicalTrials.gov

11. Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

    The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ul…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic Arizona, Scottsdale, Arizona

    Locations

    24 in total

    Run by

    Mayo Clinic

    See if you can join NCT05230173 on ClinicalTrials.gov

12. Low Dose IL-2 for the Treatment of Crohn's Disease

    The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe crohn's disease.

    Stage

    Phase 1

    Ages

    12 to 80

    Site

    Boston Children's Hospital, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Boston Children's Hospital

    See if you can join NCT04263831 on ClinicalTrials.gov

13. Autologous Stem Cell Transplant for Crohn's Disease

    Crohn's Disease (CD) is an inflammatory bowel disease. It can lead to significant complications and discomfort in the stomach and intestines. Crohn's disease is a debilitating, incurable disease of immune cells; it affects almost 1 million people in the United States. CD is characterized by inflamm…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Run by

    Aaron Etra

    See if you can join NCT03219359 on ClinicalTrials.gov

14. Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease

    This research is studying whether changing an individual's behaviors may have an impact as a treatment or outcome for inflammatory bowel disease. This research will increase the understanding of the role of a self-management program in improving health and health-related quality of life for patient…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Micigan, Ann Arbor, Michigan

    Run by

    University of Michigan

    See if you can join NCT07456566 on ClinicalTrials.gov

15. Cranberry and Gut Health in Crohn's Disease

    This study is investigating whether a cranberry-based dietary supplement, rich in polyphenols and fiber, can enhance gut health in individuals with Crohn's disease. People with Crohn's disease often have an imbalance in their gut microbiome (the community of bacteria in the gut). Previous research …

    Stage

    EARLY_Phase 1

    Ages

    18 to 65

    Site

    UMASS medical center, Worcester, Massachusetts

    Run by

    Ana Maldonado-Contreras

    See if you can join NCT07170462 on ClinicalTrials.gov

16. Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

    This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 participants with stricturing CD.

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Digestive & Liver Center of Florida, Orlando, Florida

    Locations

    5 in total

    Run by

    Alimentiv Inc.

    See if you can join NCT06997965 on ClinicalTrials.gov

17. Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

    Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pain, diarrhea, blood in the stool, weight loss, or delayed growth in children. While the exact cause …

    Stage

    Phase 4

    Ages

    6 to 17

    Site

    Phoenix Children's Hospital, Phoenix, Arizona

    Locations

    26 in total

    Run by

    Connecticut Children's Medical Center

    See if you can join NCT05781152 on ClinicalTrials.gov

18. Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

    This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of …

    Stage

    Not phased

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT04751396 on ClinicalTrials.gov

19. Precise Infliximab Exposure and Pharmacodynamic Control

    Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD). There are limited treatment options approved for use in children and adults with Crohn's disease. Physicians need better ways to inform decisions on treatment. The ma…

    Stage

    Phase 2

    Ages

    6 to 22

    Site

    Children's Hospital of Los Angeles, Los Angeles, California

    Locations

    11 in total

    Run by

    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT05660746 on ClinicalTrials.gov

20. Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)

    This is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (IBD) patients with gut inflammation and a control cohort of pediatric patients with disorders of the brain-gut interactions (DBGI) with no detectable gut in…

    Stage

    Not phased

    Ages

    6 to 21

    Site

    Seattle Children's Hospital, Seattle, Washington

    Run by

    Seattle Children's Hospital

    See if you can join NCT06315179 on ClinicalTrials.gov

21. COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

    The purpose of the study is to compare the clinical effectiveness and safety of newer inflammatory bowel disease (IBD) medications in anti-tumor necrosis factor (TNF) refractory patients with pediatric IBD (PIBD). Refractory means that there was no clinical response to anti-tumor necrosis factor (T…

    Stage

    Not phased

    Ages

    1 to 18

    Site

    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

    Locations

    4 in total

    Run by

    University of North Carolina, Chapel Hill

    See if you can join NCT07198113 on ClinicalTrials.gov

22. Therapeutic Endpoint in Pediatric IBD Conditions

    The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory respo…

    Stage

    Not phased

    Ages

    6 to 21

    Site

    Children's National Health System, Washington D.C., District of Columbia

    Run by

    Children's National Research Institute

    See if you can join NCT06065228 on ClinicalTrials.gov

23. Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

    The purpose of this study is to use diet and an injectable medication called tirzepatide (Zepbound) glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP-GLP-1 RA) medication as adjunctive therapy (another treatment used together with the primary treatment) …

    Stage

    Phase 4

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Run by

    University of Miami

    See if you can join NCT06774079 on ClinicalTrials.gov

24. Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

    In this study twenty-five (25) subjects with Crohn's disease scheduled for possible surgical intervention will be recruited for this study and a PET/MR scan using the collagen-binding radiotracer will be performed. The study aims to establish the performance figures of PET/MR using [68Ga]CBP8-PET f…

    Stage

    Not phased

    Ages

    18 to 99

    Site

    Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT06252493 on ClinicalTrials.gov

25. Impact of Prebiotics in Ulcerative Colitis

    The cause of inflammatory bowel disease (IBD) is currently unknown, although partly attributed to interactions among genetic risk polymorphisms, environmental factors, gut microbiome, and host immunity. Diet, particularly those with plant-based products, have been shown in prior research to improve…

    Stage

    Not phased

    Ages

    18 to 85

    Site

    UCLA, Los Angeles, California

    Run by

    University of California, Los Angeles

    See if you can join NCT06495658 on ClinicalTrials.gov